===
EQS-Ad-hoc: CS MEDICA / Key word(s): IPO
CS MEDICA A/S Plans Stock Spin-Off and Listing of CANNORDIC A/S
10-Jun-2024 / 14:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News
- a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
CS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing
bioactive CBD, today announced its plans to spin off and list its subsidiary CANNORDIC A/S on the German Stock Market
(Intention to Float).

CS MEDICA ("CS MEDICA" or "The Company") aims to elevate the value of CS MEDICA's shares, targeting a preliminary
valuation of CANNORDIC of MDKK 224. This is a Compliant Publication according to Article 17 MAR of Regulation (EU) No
596/2014.

The Board Members of CS MEDICA, with ISIN DK0061668225, announced the approval to spin off its wholly-owned subsidiary
CANNORDIC A/S and to initiate preparations for a separate listing on one of the stock exchange-regulated trading venues
in Germany.

Based on the pre-market sounding conducted during several roadshows in different German cities and the expressions of
interest from institutional and semi-institutional investors, CS MEDICA anticipates raising up to MDKK 45 (EUR 6
million) in the pre-IPO phase of the spin-off. As part of the initial public offering (IPO), the first step involves
placing up to 20% of CANNORDIC A/S shares with institutional and semi-institutional investors during the pre-IPO phase.
The management will continuously evaluate the placement of additional shares during the post-market launch, maintaining
the majority of the share capital of CANNORDIC A/S. This strategic move aims to secure initial investment and generate
interest from key market players before the shares are publicly available.

Key Highlights:
. Spin-off Details: Up to 20% of CANNORDIC A/S shares will be spun off.
. Valuation and Funding: Pre-market sounding indicates a valuation of CANNORDIC A/S of MDKK 224 (EUR 30
million).
. Market Positioning: The spin-off aims to enhance the market positioning of both entities.
. Shareholder Approval: The transaction is subject to approval at an extraordinary general assembly.

. Transaction Timeline: The transaction and stock market listing are planned to be completed by the end of
2024.

"The decision to list CANNORDIC A/S on the German stock market is a strategic milestone for us. This spin-off
underscores the commitment to leveraging market opportunities and aligning operations with the stringent requirements
of the new EU MDR (Medical Device Regulation), ensuring sustained growth and market leadership. Additionally, it
highlights the value of CS MEDICA's stock and will enhance our market presence, providing the necessary funding to
accelerate our growth and innovation objectives", stated Lone Henriksen, CEO of CS MEDICA A/S.

Background Information for the Suggested Strategic Initiatives
CS MEDICA is a Group specializing in IPR management and strategic oversight, supporting its entities, while CANNORDIC
specializes in R&D, MDR compliance, registration, manufacturing, and commercialization for greater efficiency.

"By listing CANNORDIC on the German Stock Exchange, we aim to advance its profile and reach its right potential in
market valuation, attracting investors and partners on the most mature, well-fitted market in Europe for the Company's
portfolio. This strategic initiative is expected to unlock the potential market value, increasing shareholder value for
both the CS MEDICA Group and CANNORDIC. By raising up to MDKK 45 (EUR 6 million), we will also secure growth capital to
accelerate and strengthen our market position." Lone Henriksen continues.

The extraordinary general assembly to approve this transaction is scheduled for June 2024. Additional details regarding
the planned spin-off of the wholly-owned subsidiary CANNORDIC A/S will be published throughout the IPO process to keep
all stakeholders informed and up to date.

About CS MEDICA A/S
CS MEDICA, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain
management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from
innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship
CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for
both human and veterinary health globally.
The Group company is listed on Spotlight Stock Market in Stockholm (symbol: "CSMED"). For more information, visit
cs-medica.com and LinkedIn.
https://www.cs-medica.com/


About CANNORDIC A/S
CANNORDIC, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based
medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science,
technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company
ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.
www.cannordic.com
End of Inside Information
10-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press
Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      CS MEDICA 

Indiakaj 10,2
2100 Copenhagen
Denmark

Phone:        +45 70707337 
E-mail:       info@cs-medica.com 
Internet:     https://www.cs-medica.com 
ISIN:         DK0061668225 
WKN:          A3CYEQ 
Listed:       Regulated Unofficial Market in Frankfurt, Munich, Stuttgart 
EQS News ID:  1921743 

End of Announcement EQS News Service
===
1921743 10-Jun-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1921743&application_name=news

END) Dow Jones Newswires

June 10, 2024 08:06 ET (12:06 GMT)